B+
Bull case
30%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-07-11 · RankAlpha Sentiment Codex
SI
Shoulder InnovationsBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The best-supported bull case is that Q1 showed real commercial traction rather than a one-off beat: 65% revenue growth, 51% implant volume growth, higher ASP, margin expansion, and a raised full-year revenue outlook suggest the launch/commercial engine is working [#SEC-8K-2026-05-13].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.0.
What can break
Operating losses widened in Q1 2026 despite strong top-line growth, showing that commercial scale has not yet translated into operating leverage [#SEC-8K-2026-05-13].
Momentum
50
Value
37
Sentiment
78
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.75 · Bull $24.00 · Bear $15.00Analysis 2026-07-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $26.25
Why
Momentum50 · Δ7d -22.9
Value37 · Δ7d -0.0
Sentiment78 · Δ7d +6.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +6.0.
Contradictions & invalidation
- • Operating losses widened in Q1 2026 despite strong top-line growth, showing that commercial scale has not yet translated into operating leverage [#SEC-8K-2026-05-13].
- • Peer set quality is loose and low coverage reduces confidence in valuation triangulation and revision tracking.
- • The bear case is that SI remains an early commercial-stage medtech name with meaningful execution risk: SG&A rose 73%, R&D rose 137%, and operating loss widened to $9.0 million in Q1, so any slowdown in surgeon adoption or customer adds could pressure the equity quickly [#SEC-8K-2026-05-13].
Catalyst clock
2026-08-15
Q1 2026 growth print and raised FY2026 revenue outlook support near-term follow-through
Lead driver: Sentiment · See AI snapshot
Momentum
50
9% active weight
Current posture
7d trendSoftening
Δ7d
-22.9
Δ21d
-31.4
Value
37
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-7.4
Sentiment
78
62% active weight
Current posture
7d trendImproving
Δ7d
+6.0
Δ21d
+18.0
Why this grade
Composite grade B. Momentum 50.4 / Value 36.6 / Sentiment 78.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-11. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$21.75
Analysis reference price unavailable
Analysis 2026-07-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-07-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$414.71M
Beta
-
Shares Out
20.82M
P/E (TTM) · Derived
-10.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.64
Rev YoY
+56.0%
EPS YoY
-48.1%
Gross Margin
+70.5%
Op Margin
-58.5%
Net Debt
-$109.28M
Current Ratio
10.71
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data